Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 107
Filter
1.
Vet Immunol Immunopathol ; 233: 110192, 2021 Mar.
Article in English | MEDLINE | ID: mdl-33476924

ABSTRACT

Mycoplasma gallisepticum (MG) infection alone or in combination with other pathogens have brought huge economic losses to the poultry industry. The intestinal microbiota plays a critical role in host defence against respiratory infection. To explore the role of intestinal microbiota in MG-induced inflammation-mediated lung injury and secondary Escherichia coli infection, MG infection model and fecal microbiota transplantation model were developed. The results showed that MG infection changed gut microbiota composition along with lung inflammation injury. Fecal microbiota transplantation from chickens infected with MG to antibiotics cocktail treated chickens decreased host defense against Escherichia coli due to impaired intestinal mucosal barrier, downregulated the mRNA expression levels of host defense enzymes and blocked autophagic flux. Lactobacillus salivarius intake alleviated lung inflammation injury caused by MG infection and increased host defense against Escherichia coli by improved gut microbiota composition. These results highlighted the role of gut microbiota in MG-infection induced lung inflammation injury and secondary infection that offered a new strategy for preventive intervention against MG infection.


Subject(s)
Chickens , Escherichia coli Infections/veterinary , Gastrointestinal Microbiome , Ligilactobacillus salivarius/physiology , Mycoplasma Infections/veterinary , Mycoplasma gallisepticum , Poultry Diseases/prevention & control , Animals , Chromatin Immunoprecipitation/veterinary , Disease Susceptibility , Escherichia coli Infections/etiology , Escherichia coli Infections/microbiology , Escherichia coli Infections/prevention & control , Inflammation/immunology , Inflammation/prevention & control , Inflammation/veterinary , Lung Diseases/microbiology , Lung Diseases/prevention & control , Lung Diseases/veterinary , Macrophages, Peritoneal/immunology , Mycoplasma Infections/complications , Mycoplasma Infections/microbiology , Mycoplasma Infections/therapy , Poultry Diseases/microbiology
3.
Transpl Infect Dis ; 22(2): e13249, 2020 Apr.
Article in English | MEDLINE | ID: mdl-31977151

ABSTRACT

Heart transplantation (HT) has been rarely performed in patients with infective endocarditis (IE) and is considered a "last resort" procedure. Orthotropic HT with bicaval technique was performed in a man with culture-negative endocarditis. Mycoplasma hominis was later detected using 16S ribosomal DNA PCR from surgically removed valve tissue. Literature review and previous results are summarized. HT may be considered as salvage treatment in selected patients with intractable IE. In cases when there is no growth in culture, 16S ribosomal DNA PCR sequencing can be used to identify the pathogen in excised valvular tissue. Mycoplasma spp. is extremely uncommon and difficult to diagnose cause of infective endocarditis (IE). There are no proposed or defined criteria for heart transplantation (HT) in patients with refractory IE, and HT has been rarely performed in this setting. We report a case of M hominis prosthetic valve endocarditis diagnosed by 16S ribosomal DNA PCR in a patient who underwent a salvage HT. We reviewed in the literature other cases of IE caused by Mycoplasma spp.


Subject(s)
Endocarditis, Bacterial/therapy , Heart Transplantation , Mycoplasma Infections/therapy , Prosthesis-Related Infections/microbiology , Salvage Therapy/methods , Adult , Anti-Bacterial Agents/therapeutic use , DNA, Bacterial/genetics , Heart Valve Prosthesis/adverse effects , Humans , Male , Mycoplasma hominis , Prosthesis-Related Infections/surgery , RNA, Ribosomal, 16S/genetics
4.
Int Orthop ; 44(2): 199-213, 2020 02.
Article in English | MEDLINE | ID: mdl-31792575

ABSTRACT

PURPOSE: Septic arthritis caused by Mycoplasma is rare. The diagnosis and effective treatment of mycoplasmal septic arthritis remains a serious problem for clinicians. The aim of this systematic review was to document the available evidence on the diagnosis and treatment methods for mycoplasmal septic arthritis and to provide guidance for clinicians. METHODS: The PubMed, EMBASE, and Cochrane Library databases were searched in December 2018.The searches were limited to the English language. Article screening and data extraction and compilation were conducted by two independent reviewers. All the included studies were assessed using the Methodological Index for Non-randomized Studies (MINORS) tool. RESULTS: There was a total of 33 articles including 34 cases of mycoplasmal septic arthritis and eight of them were periprosthetic joint infection (PJI). Twenty-four patients (70.6%) were immunocompromised, and the synovial fluid white blood cell (WBC) count was significantly lower in the immunocompromised group than in the immunocompetent group (48,527 × 106/L vs. 100,640 × 106/L; P = 0.009). The traditional culture method took longer, and the positivity rate was lower than that of nucleic acid testing (50% vs. 100%; P = 0.016). Only 19.2% (5/26) of patients treated with empiric antibiotics were relieved of symptoms, while 82.4% (28/34) of patients achieved satisfactory results after being treated with antibiotics against Mycoplasma. CONCLUSION: The possibility of mycoplasmal septic arthritis should be considered if patients with joint infections have a history of immunocompromised, repeated negative cultures, and poor empiric antibiotic treatment results. The rational use of nucleic acid testing technologies can help in the clinical diagnosis and treatment of mycoplasmal septic arthritis.


Subject(s)
Arthritis, Infectious/diagnosis , Arthritis, Infectious/therapy , Mycoplasma Infections/diagnosis , Mycoplasma Infections/therapy , Arthritis, Infectious/microbiology , Humans , Mycoplasma Infections/microbiology
8.
Indian J Dermatol Venereol Leprol ; 85(5): 441-447, 2019.
Article in English | MEDLINE | ID: mdl-31389367

ABSTRACT

Despite adequate treatment of reproductive tract infection, there is persistence of symptoms in some patients. This raises the possibility of existence of other silent microbes with pathogenic potential. Apart from the common sexually transmitted organisms such as Chlamydia trachomatis and Neisseria gonorrhoeae, there are other silent and emerging pathogens, like genital mycoplasma, which have been associated with cervicitis, pelvic inflammatory disease, infertility, and pregnancy-related complications in women. Although these organisms were identified decades ago, they are still overlooked or ignored. There is a need to understand the role played by these organisms in Asian populations and their susceptibility to the standard line of treatment. Data on genital mycoplasma infections in Indian women is heterogeneous, with limited evidence of pathogenicity. Although known for their wide spectrum of reproductive morbidities in western counterparts, these microorganisms are yet to gain the attention of Indian clinicians and microbiologists. There is paucity of adequate information in India regarding these infections, so Indian literature was compiled to get an overview of these pathogens, their association with reproductive morbidities, and their response to treatment. Thus, there is a need to explore genital mycoplasma infections in Indian women, especially in the arena of antimicrobial resistance among genital mycoplasma, which has the potential to become a major problem. A literature search with keywords focusing on "genital mycoplasma", "sexually transmitted infections India", "sexually transmitted mycoplasma", and "characteristic of mycoplasma" was carried out through computerized databases like PubMed, MEDLINE, Embase, and Google Scholar.


Subject(s)
Genital Diseases, Female/epidemiology , Mycoplasma Infections/epidemiology , Sexually Transmitted Diseases/epidemiology , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Drug Resistance, Bacterial/drug effects , Drug Resistance, Bacterial/physiology , Female , Genital Diseases, Female/diagnosis , Genital Diseases, Female/therapy , Humans , India/epidemiology , Mycoplasma Infections/diagnosis , Mycoplasma Infections/therapy , Prevalence , Sexually Transmitted Diseases/diagnosis , Sexually Transmitted Diseases/therapy , Treatment Outcome
9.
Enferm Infecc Microbiol Clin (Engl Ed) ; 37(8): 525-534, 2019 Oct.
Article in English, Spanish | MEDLINE | ID: mdl-30878312

ABSTRACT

Sexually transmitted infections caused by Chlamydia trachomatis, including lymphogranuloma venereum and Mycoplasma genitalium have increased in last decade. This epidemiological scenario presents new challenges in order to improve and strengthen our control and prevention strategies. The routine clinical diagnosis of urethritis and cervicitis must be combined with the active search for the causal agent in men with symptoms of dysuria or proctitis, and in women with pelvic inflammatory disease. We should also include sexually transmitted infections screening in asymptomatic patients with sexual risk behaviours or sexual contact with patients diagnosed with an sexually transmitted infection. The microbiological diagnosis must be based on molecular techniques capable of detecting Chlamydia trachomatis (discriminating between L genotypes associated with lymphogranuloma venereum and other genotypes) and Mycoplasma genitalium (ideally including the identification of macrolide-resistant strains). A faster and specific diagnosis will allow for a targeted treatment with a suitable antibiotic regimen. We also recommend including contact tracing of sexual partners and, occasionally, a cure test. Finally, sexually transmitted infection screening must be widely implemented in those population groups with a high prevalence of sexually transmitted infections.


Subject(s)
Chlamydia Infections , Chlamydia trachomatis , Lymphogranuloma Venereum , Mycoplasma Infections , Mycoplasma genitalium , Sexually Transmitted Diseases , Chlamydia Infections/diagnosis , Chlamydia Infections/epidemiology , Chlamydia Infections/therapy , Female , Humans , Lymphogranuloma Venereum/diagnosis , Lymphogranuloma Venereum/epidemiology , Lymphogranuloma Venereum/therapy , Male , Mycoplasma Infections/diagnosis , Mycoplasma Infections/epidemiology , Mycoplasma Infections/therapy , Sexually Transmitted Diseases/diagnosis , Sexually Transmitted Diseases/epidemiology , Sexually Transmitted Diseases/therapy
10.
J Dtsch Dermatol Ges ; 17(3): 287-315, 2019 Mar.
Article in English | MEDLINE | ID: mdl-30920748

ABSTRACT

Worldwide, the incidence of bacterial sexually transmitted infections (STIs) has shown a significant increase in recent years. In Germany, this circumstance is reflected by a rise in the number of reported syphilis cases. There has also been an uptick in the incidence of non-notifiable STIs such as gonorrhea and infections caused by Chlamydia trachomatis and Mycoplasma genitalium. A key factor in the spread of these infections is their varied clinical presentation, which includes urogenital, pharyngeal and rectal involvement as well as a large number of asymptomatic cases. New real-time multiplex PCR methods allow for rapid and targeted detection of STI pathogens. The most common bacterial STI is urogenital chlamydial infection caused by serovars D-K, which affects young adults in particular. Lymphogranuloma venereum (LGV) caused by L serovars often presents as chlamydial proctitis. In recent years, Neisseria (N.) gonorrhoeae has shown a significant development of resistance, with high-level monoresistance and multiresistance to antibiotics commonly used for treatment. It is therefore imperative that sensitivity testing of N. gonorrhoeae be performed in addition to nucleic acid amplification tests (NAATs). Increased drug resistance has also been observed for Mycoplasma genitalium, a fact that complicates treatment.


Subject(s)
Bacterial Infections/therapy , Mycoplasma Infections/epidemiology , Sexually Transmitted Diseases/therapy , Bacterial Infections/diagnosis , Bacterial Infections/epidemiology , Chlamydia Infections/diagnosis , Chlamydia Infections/epidemiology , Chlamydia Infections/therapy , Contact Tracing , Female , Gonorrhea/diagnosis , Gonorrhea/epidemiology , Gonorrhea/therapy , Humans , Male , Mycoplasma Infections/diagnosis , Mycoplasma Infections/therapy , Sexually Transmitted Diseases/diagnosis , Sexually Transmitted Diseases/epidemiology , Syphilis/diagnosis , Syphilis/epidemiology , Syphilis/therapy , Syphilis Serodiagnosis
11.
Rev Med Suisse ; 14(624): 1893-1897, 2018 Oct 24.
Article in French | MEDLINE | ID: mdl-30375790

ABSTRACT

Mycoplasma genitalium (MG) is a sexually transmitted pathogen with a poorly understood natural history. Often asymptomatic, it has been associated with urogenital conditions. The implementation of NAAT (Nucleic Acide Amplification Test) has not only improved the detection of MG, but also brought to light the emergence of antibiotic resistances, hence challenging the proposed treatment strategies and questioning the indication for systematic screening. This article summarizes current knowledge on MG among women, over viewing incidence, prevalence and clinical implications. It resumes the last guidelines in terms of screening and treatment.


Mycoplasma genitalium (MG) est un pathogène sexuellement transmissible souvent asymptomatique, dont la pathogénicité est méconnue. Source croissante d'intérêt car mieux détecté depuis l'implémentation des NAAT (Nucleic Acide Amplification Test), MG serait incriminé dans diverses pathologies uro-génitales. L'émergence des résistances aux antibiotiques est un enjeu de taille dans le traitement de l'infection et soulève le débat sur l'utilité d'un dépistage systématique. Cet article résume l'état des connaissances actuelles au sujet de MG chez la femme : son incidence, sa prévalence ainsi que ses implications cliniques. Il fait la synthèse des dernières recommandations en termes de dépistage et de traitement.


Subject(s)
Mycoplasma Infections , Mycoplasma genitalium , Female , Humans , Mass Screening , Mycoplasma Infections/diagnosis , Mycoplasma Infections/epidemiology , Mycoplasma Infections/therapy , Prevalence
12.
14.
J Neurosurg Pediatr ; 19(5): 620-624, 2017 May.
Article in English | MEDLINE | ID: mdl-28291426

ABSTRACT

Mycoplasma hominis is a rare causative pathogen for surgical site infections after neurosurgical procedures. This organism lacks a cell wall, rendering it undetectable by Gram staining and making it resistant to beta-lactam antibiotics. In addition, some special techniques are required to identify this organism. Thus, it is very difficult to diagnose infections caused by this pathogen. Here, the authors report a pediatric case of M. hominis ventriculoperitoneal shunt (VPS) infection with central nervous system involvement for which beta-lactam antibiotics were not effective and Gram staining revealed no pathogens. Because few cases have been described that involve the treatment of M. hominis infection after neurosurgery, in this case the patient's serum and CSF were monitored for antibiotic drug concentrations. Successful treatment of the infection was achieved after approximately 6 weeks of administration of clindamycin and ciprofloxacin antibiotics in addition to external ventricular drain revision and subsequent VPS replacement. When beta-lactam antibiotics are ineffective and when Gram staining cannot detect the responsible pathogens, it is important to consider M. hominis as the atypical pathogen.


Subject(s)
Mycoplasma Infections/diagnosis , Mycoplasma Infections/therapy , Mycoplasma hominis , Prosthesis-Related Infections/diagnosis , Prosthesis-Related Infections/therapy , Ventriculoperitoneal Shunt/adverse effects , Child , Diagnosis, Differential , Female , Humans , Hydrocephalus/surgery , Mycoplasma Infections/cerebrospinal fluid , Mycoplasma Infections/pathology , Neurosurgical Procedures/adverse effects , Prosthesis-Related Infections/cerebrospinal fluid , Prosthesis-Related Infections/pathology
15.
J Perinat Med ; 45(5): 505-515, 2017 Jul 26.
Article in English | MEDLINE | ID: mdl-28099135

ABSTRACT

Mycoplasmata have been linked to pregnancy complications and neonatal risk. While formerly a limited number of species could be discovered by cultures, molecular biology nowadays discovers both lower quantities and more diverse species, making us realize that mycoplasmata are ubiquitous in the vaginal milieu and do not always pose a danger for pregnant women. As the meaning of mycoplasmata in pregnancy is not clear to many clinicians, we summarized the current knowledge about the meaning of different kinds of mycoplasmata in pregnancy and discuss the potential benefits and disadvantages of treatment. Currently, there is no general rule to screen and treat for mycoplasmata in pregnancy. New techniques seem to indicate that Ureaplasma parvum (Up), which now can be distinguished from U. urealyticum (Uu), may pose an increased risk for preterm birth and bronchopulmonary disease in the preterm neonate. Mycoplasma hominis (Mh) is related to early miscarriages and midtrimester abortions, especially in the presence of abnormal vaginal flora. Mycoplasma genitalium (Mg) is now recognized as a sexually transmitted infection (STI) that is involved in the causation of cervicitis, pelvic inflammatory disease (PID) in non-pregnant, and preterm birth and miscarriages in pregnant women, irrespective of the presence of concurrent other STIs, like Chlamydia or gonorrhoea. Proper studies to test for efficacy and improved pregnancy outcome are scarce and inconclusive. Azythromycin is the standard treatment now, although, for Mg, this may not be sufficient. The role of clarithromycin in clinical practice still has to be established. There is a stringent need for new studies based on molecular diagnostic techniques and randomized treatment protocols with promising and safe antimicrobials.


Subject(s)
Mass Screening , Mycoplasma Infections/diagnosis , Pregnancy Complications, Infectious/diagnosis , Ureaplasma Infections/diagnosis , Anti-Bacterial Agents/therapeutic use , Female , Humans , Mycoplasma Infections/epidemiology , Mycoplasma Infections/microbiology , Mycoplasma Infections/therapy , Pregnancy , Pregnancy Complications, Infectious/epidemiology , Pregnancy Complications, Infectious/microbiology , Pregnancy Complications, Infectious/therapy , Ureaplasma Infections/epidemiology , Ureaplasma Infections/microbiology , Ureaplasma Infections/therapy
17.
J Pak Med Assoc ; 66(8): 1039-41, 2016 Aug.
Article in English | MEDLINE | ID: mdl-27524547

ABSTRACT

This review describes the association of balanoposthitis with diabetes. It reviews the multifaceted relationship of both conditions, and summarizes the etiology, clinical features and treatment options for this condition. The commonest etiology of balanoposthitis in males with diabetes is Candida, and the mainstay of treatment is maintenance of hygiene, euglycaemia, and eradication of infection. The review sensitizes diabetes care providers to take a history and perform a physical examination in persons with penile symptoms, and also encourages dermatology care providers to screen for diabetes in such persons.


Subject(s)
Balanitis/diagnosis , Diabetes Complications/diagnosis , Diabetes Mellitus/therapy , Hypoglycemic Agents/therapeutic use , Reproductive Tract Infections/diagnosis , Anti-Infective Agents/therapeutic use , Balanitis/complications , Balanitis/therapy , Candidiasis/complications , Candidiasis/diagnosis , Candidiasis/therapy , Diabetes Complications/therapy , Humans , Male , Mycoplasma Infections/complications , Mycoplasma Infections/diagnosis , Mycoplasma Infections/therapy , Penile Diseases/complications , Penile Diseases/diagnosis , Penile Diseases/therapy , Reproductive Tract Infections/complications , Reproductive Tract Infections/therapy , Staphylococcal Infections/complications , Staphylococcal Infections/diagnosis , Staphylococcal Infections/therapy , Streptococcal Infections/complications , Streptococcal Infections/diagnosis , Streptococcal Infections/therapy , Trichomonas Infections/complications , Trichomonas Infections/diagnosis , Trichomonas Infections/therapy
20.
Asian J Endosc Surg ; 9(2): 146-8, 2016 May.
Article in English | MEDLINE | ID: mdl-27117965

ABSTRACT

A 59-year-old man developed a high fever, elevated white blood cell count, elevated C-reactive protein level, and perineal pain 5 days after robot-assisted laparoscopic radical prostatectomy. Treatment with cefmetazole was ineffective. A urine specimen was submitted for culture on postoperative day 7, and Mycoplasma hominis (M. hominis) was detected 1 week later. Cefmetazole was therefore switched to quinolone. The clinical symptoms and laboratory data immediately showed marked improvement. M. hominis has been shown to inhabit the genitourinary tract. Although it is considered to induce urethritis, its pathogenicity in healthy male subjects has not been investigated. M. hominis is difficult to detect and is resistant to ß-lactams because it lacks a cell wall. Urine culture sometimes results in false-negative results. In cases where empirical therapy for postoperative infection is ineffective, surgeons should recognize the possibility of M. hominis involvement and consider changing the antibiotic used.


Subject(s)
Laparoscopy/adverse effects , Mycoplasma Infections/etiology , Mycoplasma hominis , Prostatectomy/adverse effects , Robotic Surgical Procedures/adverse effects , Surgical Wound Infection/etiology , Humans , Male , Middle Aged , Mycoplasma Infections/diagnosis , Mycoplasma Infections/therapy , Surgical Wound Infection/diagnosis , Surgical Wound Infection/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...